The latest update is out from Vaxcyte ( (PCVX) ).
On March 31, 2025, Vaxcyte announced positive results from its Phase 2 study of VAX-24, a 24-valent pneumococcal conjugate vaccine candidate for infants, showing it was well-tolerated and elicited strong immune responses. The company plans to advance the VAX-24 Mid dose to a potential Phase 3 program, pending further study results, and has also announced the development of VAX-XL, a third-generation PCV candidate. These developments reinforce Vaxcyte’s commitment to expanding vaccine coverage and addressing the global burden of pneumococcal disease, with significant implications for future clinical programs and market positioning.
More about Vaxcyte
Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on engineering high-fidelity vaccines to protect against bacterial diseases. The company is developing pneumococcal conjugate vaccines (PCVs) to address invasive pneumococcal disease, with a market focus on both infant and adult populations.
YTD Price Performance: -16.61%
Average Trading Volume: 1,140,044
Technical Sentiment Signal: Buy
Current Market Cap: $8.94B
For detailed information about PCVX stock, go to TipRanks’ Stock Analysis page.